Ligand Pharmaceuticals Inc. (LGND)
| Market Cap | 2.60B |
| Revenue (ttm) | 274.65M |
| Net Income (ttm) | 68.32M |
| Shares Out | 16.71M |
| EPS (ttm) | 4.05 |
| PE Ratio | 38.39 |
| Forward PE | 30.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,311 |
| Open | 154.70 |
| Previous Close | 154.30 |
| Day's Range | 153.39 - 156.56 |
| 52-Week Range | 89.18 - 219.75 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 211.71 (+36.3%) |
| Earnings Date | Nov 9, 2021 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treat...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 211.71, which is an increase of 36.31% from the latest price.
News
Ligand's (LGND) Drug-Developing Technologies Holds Potential
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb
Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.
Ligand Pharmaceuticals (LGND) Beats Q3 Earnings and Revenue Estimates
Ligand (LGND) delivered earnings and revenue surprises of 54.90% and 7.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Ligand Reports Third Quarter 2021 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports Third Quarter 2021 Financial Results
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
5 Biotech Stocks With 105% to 386% Upside, According to Wall Street
Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.
Ligand to Report Third Quarter Financial Results on November 9, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Third Quarter Financial Results on November 9, 2021
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand's BEPro...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic using Ligand's BEPro Technology™
Helping Your Kid Pay for College? Check Out This Podcast.
And a look at stocks that provided great lessons.
Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Ref...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China's Natio...
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
New Strong Sell Stocks for August 5th
AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut
Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates
Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ligand Reports Second Quarter 2021 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports Second Quarter 2021 Financial Results
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower t...
PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligan...
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in ...
SAN DIEGO--(BUSINESS WIRE)---- $LGND--Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Ligand to Report Second Quarter Financial Results on July 29, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Second Quarter Financial Results on July 29, 2021
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
Ligand (LGND) Moves 3.1% Higher: Will This Strength Last?
Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...
LENZ Therapeutics Debuts With $47 Million Series A Financing
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today emerged from st...
Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?